NasdaqGM:CGEN

Stock Analysis Report

Executive Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Compugen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-4.6%

CGEN

-1.8%

US Life Sciences

1.0%

US Market


1 Year Return

17.5%

CGEN

13.5%

US Life Sciences

6.7%

US Market

Return vs Industry: CGEN exceeded the US Life Sciences industry which returned 13.5% over the past year.

Return vs Market: CGEN exceeded the US Market which returned 6.7% over the past year.


Share holder returns

CGENIndustryMarket
7 Day-4.6%-1.8%1.0%
30 Day-1.4%-4.6%-1.8%
90 Day17.5%-4.2%-1.8%
1 Year17.5%17.5%13.7%13.5%9.1%6.7%
3 Year-29.9%-29.9%79.2%77.8%46.0%36.6%
5 Year-45.8%-45.8%123.9%113.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is Compugen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Compugen undervalued based on future cash flows and its price relative to the stock market?

8.13x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate CGEN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate CGEN's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: CGEN is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: CGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate CGEN's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: CGEN is overvalued based on its PB Ratio (8.1x) compared to the US Life Sciences industry average (4.5x).


Next Steps

Future Growth

How is Compugen expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

-7.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: CGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CGEN is forecast to have no revenue next year.

High Growth Revenue: CGEN is forecast to have no revenue next year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if CGEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Compugen performed over the past 5 years?

-14.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: CGEN is unprofitable, and losses have increased over the past 5 years at a rate of -14.7% per year.

Accelerating Growth: Unable to compare CGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGEN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (45%).


Return on Equity

High ROE: CGEN has a negative Return on Equity (-84.59%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: CGEN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: CGEN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Compugen's financial position?


Financial Position Analysis

Short Term Liabilities: CGEN's short term assets ($37.8M) exceeds its short term liabilities ($7.0M)

Long Term Liabilities: CGEN's short term assets ($37.8M) exceeds its long term liabilities ($9.4M)


Debt to Equity History and Analysis

Debt Level: CGEN is debt free.

Reducing Debt: CGEN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CGEN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CGEN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CGEN has sufficient cash runway for 1.472711 years if free cash flow continues to grow at historical rates of 8.6% each year.


Next Steps

Dividend

What is Compugen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage0.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate CGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if CGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Compugen's salary, the management and board of directors tenure and is there insider trading?

2.8yrs

Average management tenure


CEO

Anat Cohen-Dayag (52yo)

9.6yrs

Tenure

US$854,003

Compensation

Dr. Anat Cohen-Dayag, Ph.D., has been the Chief Executive Officer at Compugen Ltd. since March 2010 and serves as its President since June 2009. Dr. Cohen-Dayag served as Vice President of Research & Devel ...


CEO Compensation Analysis

Compensation vs. Market: Anat's total compensation ($USD854.00K) is about average for companies of similar size in the US market ($USD1.17M).

Compensation vs Earnings: Anat's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.8yrs

Average Tenure

51.5yo

Average Age

Experienced Management: CGEN's management team is considered experienced (2.8 years average tenure).


Board Age and Tenure

6.2yrs

Average Tenure

62yo

Average Age

Experienced Board: CGEN's board of directors are considered experienced (6.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Martin Gerstel (78yo)

    Senior Advisor

    • Tenure: 1.7yrs
  • Elana Holzman

    Director of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Kirk Christoffersen (50yo)

    Senior Vice President of Corporate & Business Development

    • Tenure: 2.8yrs
    • Compensation: US$639.39k
  • Anat Cohen-Dayag (52yo)

    CEO, President & Director

    • Tenure: 9.6yrs
    • Compensation: US$854.00k
  • Dorit Amitay (51yo)

    Vice President of Human Resources

    • Tenure: 12.8yrs
  • Donna Gershowitz (55yo)

    General Counsel

    • Tenure: 0yrs
  • Ari Krashin (46yo)

    Chief Financial & Operating Officer

    • Tenure: 5.1yrs
    • Compensation: US$575.74k
  • Zurit Levine (51yo)

    Senior Vice President of Technology Innovation

    • Tenure: 0yrs
    • Compensation: US$356.02k
  • John Hunter (56yo)

    Chief Scientific Officer

    • Tenure: 1yrs
    • Compensation: US$602.79k
  • Henry Adewoye

    Chief Medical Officer

    • Tenure: 1.6yrs
    • Compensation: US$612.73k

Board Members

  • Sandy Zweifach (63yo)

    Director

    • Tenure: 1.3yrs
  • Arie Ovadia (71yo)

    External Director

    • Tenure: 12.3yrs
  • Paul Sekhri (61yo)

    Chairman

    • Tenure: 2yrs
  • Kinneret Savitzky (52yo)

    Director

    • Tenure: 1.3yrs
  • Drew Pardoll

    Chairman of Scientific Advisory Board

    • Tenure: 0yrs
  • Anat Cohen-Dayag (52yo)

    CEO, President & Director

    • Tenure: 9.6yrs
    • Compensation: US$854.00k
  • Yair Aharonowitz (78yo)

    External Director

    • Tenure: 12.3yrs
  • Toni Ribas

    Member of Scientific Advisory Board

    • Tenure: 6.2yrs
  • Iain McInnes

    Member of Scientific Advisory Board

    • Tenure: 6.2yrs
  • Charles Drake

    Member of Scientific Advisory Board

    • Tenure: 6.2yrs

Company Information

Compugen Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Compugen Ltd.
  • Ticker: CGEN
  • Exchange: NasdaqGM
  • Founded: 1993
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$258.356m
  • Shares outstanding: 61.96m
  • Website: https://www.cgen.com

Number of Employees


Location

  • Compugen Ltd.
  • Building D
  • 26 Harokmim Street
  • Holon
  • 5885849
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGENNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDAug 2000
CGENTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSAug 2000
CW9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2000

Biography

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company’s the ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 01:26
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)